Alector reported a net income of $124.6 million, or $1.11 per share, for the quarter ended September 30, 2026, compared to a net loss of $34.7 million in the prior-year period. The result was driven by $162.9 million in collaboration revenue recognized following the termination of its agreement with GSK. The company also entered an exclusive global license for AL050 with Genentech, receiving a $100 million upfront payment and eligibility for up to $1.17 billion in milestones. Additionally, Alector completed an underwritten equity offering raising approximately $75 million. Combined cash, cash equivalents, and investments are expected to reach roughly $213.7 million, funding operations into the second half of 2029. The company is a biotechnology firm developing therapies for neurodegenerative diseases.
